SEC Form 4	
------------	--

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burde	n
hours per response:	0.5

	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
--	--

FORM 4

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

1. Name and	Address of F	Reporting Person*			_		r Name and									g Perso	on(s) to Issi	Jer
1. Name and Address of Reporting Person <sup>*</sup> Hochman David P						2. Issuer Name and Ticker or Trading Symbol       5. Relationship of Reporting Person(s) to Iss (Check all applicable)         Orchestra BioMed Holdings, Inc.       [ OBIO ]         X       Director       10% C											10% O	
(Last)	(Fir	st) (	-															
1 · · ·	HESTRA B	NOMED HOLD		C.	01/26/2023 See Remarks													
150 UNIC																		
(Street)			<ul> <li>4. If Amendment, Date of Original Filed (Month/Day/Year)</li> <li>6. Individual or Joint/Group Filing (Check Applicable Line)</li> <li>X Form filed by One Reporting Person</li> </ul>															
NEW HO	PE PA		18938		_	X Form filed by One Reporting Person Form filed by More than One Reporting												
(City)	(Sta	ate) (	(Zip)											Person				
		Tal	ble I - No	n-Deri	vativ	ve S	ecurities	s Ac	quired,	Dis	posed of	f, or Be	neficially	/ Owned				
1. Title of Security (Instr. 3)				2. Tran Date (Month			2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)					) Securities Beneficia Owned F	5. Amount of Securities Beneficially Owned Following		vnership I: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership
									Code	v	Amount	(A) or (D) Price		Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)
Common S ("Commor		alue \$0.0001 per	r share	01/2	26/2023				Α		135,947	7 <sup>(1)</sup> A	(2)	135	,947	D		
Common Stock				01/2	26/202	23			Α		51,342	<sup>(1)</sup> A	(3)	51,342		I		By the DPH 2008 Trust
Common Stock			01/2	26/2023				A		3,140(	<sup>1)</sup> A	(4)	3,140		I I		By the NSH 2008 Family Trust	
			Table II -											Owned			I	
Derivative Conversion Date Execution Security or Exercise (Month/Day/Year) if any		3A. Deeme Execution if any (Month/Day	d 4. Date, Transac Code (Ir		ts, calls, warrant 5. Number o Derivative Securities Acquired (A or Disposed of (D) (Instr. 3, 4 and 5)		er of ve es d (A) osed nstr.	f 6. Date Exerci Expiration Da (Month/Day/Y		sable and te	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	derivative Securitie Beneficia Owned Following Reported	re Ownersh Ps Form: ally Direct (D or Indire g (I) (Instr.	Ownershi	Beneficial Ownership ct (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisa	able	Expiration Date	Title	Amount or Number of Shares		Transac (Instr. 4)			
Nonstatutory Stock Option (Right to Buy)	\$4.3	01/26/2023			A		194,071		01/26/20	023	08/07/2028	Common Stock	194,071	(5)	194,0	071	D	
Nonstatutory Stock Option (Right to Buy)	\$4.06	01/26/2023			A		31,000		(6)		04/11/2032	Common Stock	31,000	(7)	31,0	00	D	
Nonstatutory Stock Option (Right to Buy)	\$10	01/26/2023			A		300,181		(8)		08/25/2032	Common Stock	300,181	(9)	300,181		D	
Nonstatutory Stock Option (Right to Buy)	\$10	01/26/2023			A		208,216		(10)		08/25/2032	Common Stock	208,216	(11)	208,2	216	I	By the DPH 2008 Trust
Nonstatutory Stock Option (Right to Buy)	\$10	01/26/2023			A		116,250		(12)		01/19/2023	Common Stock	116,250	(13)	116,2	250	D	
Incentive Stock Option (Right to Buy)	\$4.3	01/26/2023			A		69,750		01/26/20	023	08/07/2028	Common Stock	69,750	(14)	69,7	'50	D	
Incentive Stock Option (Right to Buy)	\$4.06	01/26/2023			A		6,743		(15)		04/11/2032	Common Stock	6,743	(16)	6,74	43	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned         (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			ate	of Securities			9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Expiration Date Date Title Of Shares			(Instr. 4)				
Warrant (Right to Buy)	<b>\$21</b> .51	01/26/2023		Α		422		01/26/2023	05/31/2023	Common Stock	422	(17)	422	D	
Warrant (Right to Buy)	\$21.51	01/26/2023		A		410		01/26/2023	05/31/2023	Common Stock	410	(18)	410	I	By the NSH 2008 Family Trust

## Explanation of Responses:

1. These securities were issued on the closing date of the merger (the "Business Combination") contemplated by the Agreement and Plan of Merger, dated as of July 4, 2022, as amended by Amendment No. 1 thereto dated as of July 21, 2022 and Amendment No. 2 thereto dated as of November 21, 2022 (as amended, the "Merger Agreement"), by and among Orchestra BioMed Holdings, Inc. (*t/k/a* Health Sciences Acquisitions Corporation 2) ("ISAC2"), IISAC Olympus Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of HSAC2, and Orchestra BioMed, Inc., a Delaware corporation ("Legacy Orchestra"), in exchange for Legacy Orchestra securities.

2. Received in the Business Combination in exchange for 292,360 shares of common stock of Legacy Orchestra ("Legacy Orchestra Common Stock")

3. Received in the Business Combination in exchange for 110,412 shares of common stock of Legacy Orchestra Common Stock.

4. Received in the Business Combination in exchange for 6.753 shares of common stock of Legacy Orchestra Common Stock.

5. Received in the Business Combination in exchange for a nonstatutory stock option to acquire 417,357 shares of Legacy Orchestra Common Stock for \$2.00 per share.

6. The nonstatutory stock options ("NSOs") vest over a three-year period as follows: (i) 33% of the underlying shares vested on the grant date and (ii) 67% of the underlying shares have vested and will vest in equal installments on a quarterly basis on the last day of each quarter, starting with the end of the first quarter after the grant date, subject to the Reporting Person's continuous service through such dates. The grant date is April 12, 2022.

7. Received in the Business Combination in exchange for a nonstatutory stock option to acquire 66,667 shares of Legacy Orchestra Common Stock for \$1.89 per share.

8. The NSOs vest over a three-year period as follows: (i) 33% of the underlying shares vested on the grant date and (ii) 67% of the underlying shares have vested and will vest in equal installments on a quarterly basis on the last day of each quarter, starting with the end of the first quarter after the grant date, subject to the Reporting Person's continuous service through such dates. The grant date is August 18, 2022.

9. Received in the Business Combination in exchange for a nonstatutory stock option to acquire 645,551 shares of Legacy Orchestra Common Stock for \$4.65 per share.

10. The NSOs vest over a three-year period as follows: (i) 33% of the underlying shares vested on the grant date and (ii) 67% of the underlying shares have vested and will vest in equal installments on a quarterly basis on the last day of each quarter, starting with the end of the first quarter after the grant date, subject to the Reporting Person's continuous service through such dates. The grant date is August 18, 2022 11. Received in the Business Combination in exchange for a nonstatutory stock option to acquire 447,776 shares of Legacy Orchestra Common Stock for \$4.65 per share.

12. The NSOs vest over a three-year period as follows: (i) 33% of the underlying shares vested on the grant date and (ii) 67% of the underlying shares have vested and will vest in equal installments on a quarterly basis on the last day of each quarter, starting with the end of the first quarter after the grant date, subject to the Reporting Person's continuous service through such dates. The grant date is January 20, 2023. 13. Received in the Business Combination in exchange for a nonstatutory stock option to acquire 250,000 shares of Legacy Orchestra Common Stock for \$4.65 per share.

14. Received in the Business Combination in exchange for an incentive stock option to acquire 150,000 shares of Legacy Orchestra Common Stock for \$2.00 per share.

15. The incentive stock options vest over a three-year period as follows: (i) 33% of the underlying shares vested on the grant date and (ii) 67% of the underlying shares have vested and will vest in equal installments on a quarterly basis on the last day of each quarter, starting with the end of the first quarter after the grant date, subject to the Reporting Person's continuous service through such dates. The grant date is April 12, 2022

16. Received in the Business Combination in exchange for an incentive stock option to acquire 14,500 shares of Legacy Orchestra Common Stock for \$1.89 per share.

17. Received in the Business Combination in exchange for warrants to purchase 907 shares of Legacy Orchestra Common Stock for \$10.00 per share.

18. Received in the Business Combination in exchange for warrants to purchase 881 shares of Legacy Orchestra Common Stock for \$10.00 per share.

## Remarks:

Chief Executive Officer and Chairperson

/s/ Matthew R. Schob, Attorney- 01/30/2023

in-Fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.